Precision BioSciences Inc. News
Novartis Follows Eli Lilly with $1.4 Billion Gene Editing Pact
Precision BioSciences is developing gene editing tools with several potential advantages over CRISPR.
This CRISPR Stock Plunged On Cell Therapy's Looming Question
A certain type of cell therapy is easier to manufacture, but may lead to worse long-term outcomes for patients.
Tips for Retirees to Deal with Falling Stocks and Bonds
The markets' slide particularly hurts retirees, who may have to sell some of their stocks and bonds to finance spending.
Alphabet CEO Pichai Continues to Sound Alarm About the Economy
The parent company of Google and Youtube is preparing for a sharp deterioration in the health of the economy.